This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Opiant Pharmaceuticals Croissance future
Future contrôle des critères 5/6
Opiant Pharmaceuticals is forecast to grow earnings and revenue by 62.6% and 39.5% per annum respectively while EPS is expected to grow by 62.9% per annum.
Informations clés
62.6%
Taux de croissance des bénéfices
62.9%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 23.6% |
| Taux de croissance des recettes | 39.5% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 15 Nov 2022 |
Mises à jour récentes de la croissance future
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003
Dec 14Opiant Pharmaceuticals receives $50M in convertible debt financing
Dec 10Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2025 | 125 | 38 | -7 | -3 | 2 |
| 12/31/2024 | 77 | 9 | -21 | -17 | 2 |
| 12/31/2023 | 37 | -23 | -31 | -27 | 2 |
| 12/31/2022 | 10 | -46 | N/A | -16 | 3 |
| 9/30/2022 | 22 | -33 | -16 | -15 | N/A |
| 6/30/2022 | 39 | -20 | -10 | -10 | N/A |
| 3/31/2022 | 46 | -6 | -2 | -2 | N/A |
| 12/31/2021 | 48 | 3 | 2 | 2 | N/A |
| 9/30/2021 | 44 | 2 | -2 | -2 | N/A |
| 6/30/2021 | 37 | -1 | -2 | -2 | N/A |
| 3/31/2021 | 32 | -3 | -1 | -1 | N/A |
| 12/31/2020 | 30 | -2 | -2 | -2 | N/A |
| 9/30/2020 | 27 | 0 | 6 | 6 | N/A |
| 6/30/2020 | 39 | 10 | 5 | 5 | N/A |
| 3/31/2020 | 39 | 12 | 6 | 6 | N/A |
| 12/31/2019 | 41 | 12 | 4 | 4 | N/A |
| 9/30/2019 | 38 | 1 | -3 | -3 | N/A |
| 6/30/2019 | 21 | -11 | -3 | -3 | N/A |
| 3/31/2019 | 18 | -14 | -4 | -4 | N/A |
| 12/31/2018 | 14 | -21 | -1 | -1 | N/A |
| 9/30/2018 | 34 | -2 | -3 | -3 | N/A |
| 6/30/2018 | 29 | -5 | -3 | -3 | N/A |
| 3/31/2018 | 30 | -3 | -5 | -5 | N/A |
| 12/31/2017 | 28 | 3 | -9 | -9 | N/A |
| 10/31/2017 | 17 | 2 | 5 | 5 | N/A |
| 7/31/2017 | 18 | 7 | 6 | 6 | N/A |
| 4/30/2017 | 15 | 6 | 7 | 7 | N/A |
| 1/31/2017 | 18 | 9 | 11 | 11 | N/A |
| 10/31/2016 | 11 | 3 | 0 | 0 | N/A |
| 7/31/2016 | 10 | -8 | N/A | -1 | N/A |
| 4/30/2016 | 10 | -8 | N/A | 0 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: OPNT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).
Bénéfices vs marché: OPNT is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: OPNT is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: OPNT's revenue (39.5% per year) is forecast to grow faster than the US market (8.1% per year).
Croissance élevée des revenus: OPNT's revenue (39.5% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if OPNT's Return on Equity is forecast to be high in 3 years time